Does Cytoreductive Therapy Reduce the Risk of Blood Clots in MPNs?

Published on

Topics include: Treatments

Patient Power community member, Joan, asks, â??What is cytoreductive therapy, and does it reduce the risk of blood clots?â?? Dr. Mark Heaney of Columbia University Medical Center answers this question by defining cytoreduction and by providing background information related to clinical trial results. Listen as Dr. Heaney discusses the role of cytoreductive therapy in the treatment of essential thrombocythemia (ET).

The Ask the Expert series is sponsored through an educational grant to the Patient Empowerment Network from Incyte Corporation.

View more programs featuring and

Produced in association with

Related Programs


What Are the Long-Term Effects of Hydroxyurea?

Dr. Bart Scott from Seattle Cancer Care Alliance discusses hydoxyurea research and the long-term safety of this medication.


Current and Future Treatments for Polycythemia Vera (PV)

From The Conversation, MPN edition, Andrew speaks with Dr. Srdan Verstovsek of MD Anderson Cancer Center and Dr. Mark Heaney of Columbia University Medical Center regarding current and investigational treatments for polycythemia vera (PV).


Join Our Community Register for Events Read Our Latest Blog

Page last updated on July 19, 2017